> South San Francisco-based Pact Pharma has enticed Tim Moore from Gilead's Kite Pharma to serve as Pact's president and chief technical officer as it develops TCR-T cell therapies for the eradication of solid tumors. Release
> Catalent and clinical-stage biotech Minerva Neurosciences have struck a deal for the CDMO to manufacture and package the finished dose form of roluperidone (MIN-101), Minerva’s investigational compound for the treatment of symptoms of schizophrenia. Release
> Cellectis, a Swiss biotech working on immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), has reached an agreement for Lonza to handle clinical manufacturing. Release
> Novasep has launched Senefill, a unit dedicated to fill-and-finish aseptic commercial operations. It is in Seneffe, Belgium. Release
> Nanoform will conduct an evaluation of its nanoparticle technology across a range of AstraZeneca’s pharmaceutical products. Release
> CapsCanada, which makes vegetarian K-CAPS, is moving its headquarters to a facility in Dania Beach, Florida. Release